argenx
Focus: argenx is a European antibody-focused biotech founded in 2008, headquartered in Belgium, specializing in neonatal Fc receptor (FcRn) blockers and immunology therapeutics. The company operates at mid-cap scale with a narrow but strategically focused commercial presence.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Open Jobs
62+7 this month
Growing — net +7 jobs in 30d
24 jobs added vs 17 removed. Steady team buildout.
Should You Work at argenx?
AI assessmentBest suited for scientists and clinical professionals seeking deep expertise in a proven platform with multiple label-expansion catalysts, but carry single-product revenue risk typical of mid-stage biotechs.
Why Work Here
- Single validated blockbuster in VYVGART (efgartigimod) generating $200M+ in Part D spending with multiple label expansion opportunities across neurology and immunology
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$200M Part DGrowing
Peak
Flagship FcRn blocker with FDA approval and multiple Phase 2/3 expansion programs underway across neurology and hematology indications.
Help build intelligence for argenx
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.